Regeneron 4Q Revenues: $1.9 billion (+22%) 4Q Earnings: $820 million (+371%) FY Revenues: $6.7 billion (+14%) FY Earnings: $ 2.4 billion (+104%) Comments: EYLEA Injection sales in the U.S. increased 11% to $1.1 billion. EYLEA sales outside the U.S., which are recorded by the Company’s collaborator Bayer, increased 14% to $724 million in the quarter. Libtayo Injection sales in the U.S. were $15 million in the first three months of launch. Dupixent Injection global net sales, which are ...